Results from a study of epratuzumab were released today. It did not meet its primary endpoint of clinically reducing the severity of lupus in people with mild to moderate disease. The following is a statement from Sandra C. Raymond, President and CEO
Lupus Foundation of America’s Collaboration in PARTNERS Seeks to Improve Pediatric Research and Care
Learn more about PARTNERS (Patients, Advocates and Rheumatology Teams Network for Research and Service), a new initiative.
Lupus Foundation of America Hosts Capitol Conversation on 21st Century Cures Moderated by Chuck Todd
National Advocacy Awards Dinner recognizes leaders from Congress, federal agencies, industry and the research community.
Lupus Foundation of America Hosts Awards Dinner & 21st Century Cures Discussion
People with lupus need and deserve a full arsenal of treatments. With many new and innovative drugs for lupus in the drug pipeline, these highly anticipated treatments will mean nothing if people with lupus cannot afford them.
The request for nominations for the Lupus Insight Prize will open January 15, 2015 and will be awarded at the Federation of Clinical Immunology Societies (FOCIS) annual meeting in San Diego this June.
Foundation-funded research studies highlighted at premier rheumatology meeting in Boston.
The Lupus Foundation of America announced four grants that will allow lupus investigators to continue critical lupus research. Another grant will be used to develop a groundbreaking diagnostic tool for children with lupus-related kidney inflammation, or lupus nephritis.